Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Sees Large Drop in Short Interest

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the target of a large decline in short interest in July. As of July 15th, there was short interest totaling 76,263 shares, a decline of 87.3% from the June 30th total of 602,285 shares. Based on an average daily volume of 1,095,213 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.6% of the shares of the stock are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Creative Medical Technology in a report on Friday, May 22nd. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Creative Medical Technology currently has an average rating of “Reduce”.

Creative Medical Technology Stock Down 0.1%

Shares of NASDAQ CELZ traded down $0.00 during mid-day trading on Friday, hitting $0.81. 97,253 shares of the company traded hands, compared to its average volume of 10,137,199. Creative Medical Technology has a 1 year low of $0.78 and a 1 year high of $6.25. The stock has a market capitalization of $3.84 million, a price-to-earnings ratio of -0.38 and a beta of 1.89. The business has a 50 day moving average of $1.69 and a two-hundred day moving average of $1.92.

Creative Medical Technology (NASDAQ:CELZ) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.01. As a group, research analysts anticipate that Creative Medical Technology will post -1.14 EPS for the current year.

Institutional Investors Weigh In On Creative Medical Technology

An institutional investor recently bought a new stake in Creative Medical Technology stock. Jane Street Group LLC purchased a new stake in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned approximately 1.17% of Creative Medical Technology as of its most recent filing with the Securities and Exchange Commission. 1.42% of the stock is currently owned by institutional investors and hedge funds.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.